Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease

Medical Xpress - latest medical and health news stories · 2h ago

New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.

Read original article on Medical Xpress - latest medical and health news stories →

Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease

Related news